HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Supplement GMP Documentation Better, But Still No. 2 On FDA Observation List – AHPA

Executive Summary

FDA revisits about a third of supplement manufacturing sites, with two-thirds coming within three years, says AHPA. Chief information analyst Merle Zimmermann says FDA increased focus on recordkeeping has resulted in an improvement and fewer problems reported since 2015

You may also be interested in...

‘Recipe For Disaster’ In Supplement Manufacturing? US DoJ Attorney Cooks Up Likely Causes

"You end up with a recipe for maybe there's adulterants in the product. Maybe the product wasn't manufactured according to the spec, so it's misbranded. Worse, there could be adulterants. In some of those ingredients, there's a lot of potential failures,” says Patrick Runkle, senior litigation counsel at DoJ Consumer Protection Branch, during FDL conference.

FDA Raps Supplement Maker Marco Pharma For GMP Violations Surfaced During Inspection

The US Food and Drug Administration directs Marco Pharma International to correct GMP compliance issues identified during a May 2019 site inspection, including quality control and recordkeeping failures, in a warning letter made public 4 February.

Sea&Ski Sunscreen Firm Warned About GMP Violations, Acne, Eczema Claims

Cross Brands violated GMP including verifying the identity of ingredients and made acne- and eczema-treatment label claims for products not covered under the OTC drug monograph, says FDA in a warning letter.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts